Memantina Zentiva

Memantine Hydrochloride, the active ingredient in Memantina Zentiva, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adult patients. It works by modulating glutamatergic neurotransmission to reduce excitotoxic neuronal damage.

GNH USA supplies Memantina Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for healthcare providers across multiple regions.

Memantine Hydrochloride is used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting cognition. - Moderate to severe Alzheimer’s disease: improves cognition, functional abilities and overall clinical status. - Alzheimer’s disease with behavioral symptoms: may reduce agitation and improve patient cooperation. - Cognitive decline in Alzheimer’s disease: provides symptomatic support for memory and thinking processes.

Memantina Zentiva may cause a range of adverse reactions. Patients should be aware of both frequent and less common events.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate cranial pain. - Constipation: reduced bowel movements. - Confusion: transient disorientation or difficulty concentrating. - Fatigue: feeling unusually tired. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Allergic reactions: rash, itching, swelling, or difficulty breathing. - Hallucinations: visual or auditory disturbances. - Cardiac arrhythmias: irregular heart rhythms. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: signs of liver injury such as jaundice.

When prescribing Memantina Zentiva, clinicians should consider several safety aspects. - Renal impairment: adjust therapy and monitor renal function. - Hepatic impairment: use with caution; monitor liver enzymes. - Cardiovascular disease: observe for blood pressure changes. - Concomitant NMDA antagonists: avoid combined use to prevent additive toxicity. - Pregnancy and lactation: safety not established; weigh potential benefits against risks. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Memantina Zentiva can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Amantadine or other NMDA antagonists: may increase neurotoxicity. - High‑dose ketamine: additive NMDA blockade. - CNS depressants (e.g., benzodiazepines): heightened sedation and confusion.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: possible additive blood pressure reduction. - Diuretics: monitor electrolyte balance. - Anticholinergic drugs: may exacerbate confusion. - SSRIs or SNRIs: watch for increased serotonergic effects. - Antiepileptic drugs: potential alteration of seizure threshold.